During the buildout of manufacturing capacity, we will concurrently develop human three-dimensional tissue test beds as quantitative validation platforms for process accuracy, consistency, and reproducibility, characterized by predefined release criteria including structural architecture, cell-type composition, electrophysiologic function, and molecular quality attributes. Once operating within defined process capability thresholds, these systems will replace a substantial portion of conventional animal models and two-dimensional cultures with human-relevant, functionally measurable platforms that more faithfully recapitulate extracellular matrix organization, multicellular interactions, and signaling dynamics, thereby increasing predictive validity and reducing species-driven translational attrition. As process control and performance benchmarks mature, the same infrastructure will transition to cGMP-aligned manufacturing through implementation of validated standard operating procedures, environmental monitoring, quality management systems, and regulatory documentation frameworks, allowing the platform to evolve from research-grade production to clinical-grade therapeutic manufacturing engineered for scale from inception.